Arvinas Will Present ARV-102 Biomarker Data in Seoul
New clinical data on the LRRK2 degrader for neurological conditions will be unveiled at an international congress.
Updated on Oct. 1, 2026 in Alzheimer’s
Arvinas will debut Phase 1 clinical trial data for its investigational drug ARV-102 at the 2026 International Congress of Parkinson's Disease and Movement Disorders. The presentation is scheduled to take place in Seoul, Korea, between October 4 and 8, 2026.
Why it matters
The study evaluates a PROTAC LRRK2 degrader designed to cross the blood-brain barrier, offering a potential new approach to treating protein-linked neurodegenerative diseases.
The clinical findings will be highlighted during a 5-minute oral presentation numbered LBA 15. The study focuses on ARV-102, a degrader targeting the LRRK2 protein associated with Parkinson's disease and progressive supranuclear palsy.
The players
Arvinas
Arvinas is a biopharmaceutical company headquartered in New Haven, Connecticut, that focuses on developing protein degradation therapies.
The details
Arvinas developed ARV-102 to specifically target LRRK2 proteins while maintaining the ability to penetrate the blood-brain barrier. The company, which is based in New Haven, Connecticut, will share findings via both an oral presentation and an E-Poster.
Timeline
The 2026 International Congress of Parkinson's Disease and Movement Disorders runs from October 4 to 8, 2026.
The oral presentation regarding ARV-102 study data is scheduled for October 7, 2026.
The Big Picture
This development follows the established path of research into LRRK2 kinase inhibitors for Parkinson's disease. The introduction of ARV-102 represents a technical shift by utilizing PROTAC degradation to address the protein target, moving beyond the legacy hypothesis that purely inhibited LRRK2 kinase activity.
These findings provide insight into the potential for future treatments targeting the underlying proteins associated with neurodegenerative conditions. As the drug is still in early-stage trials, there is no immediate change to current patient treatment routines or availability.
The takeaway
The presentation of these biomarkers provides early evidence for a novel approach to modulating LRRK2 protein levels in the brain. Patients and families monitoring this research should watch for subsequent trial phases to determine the long-term feasibility of this therapy.
Further reading
Learn more about the latest research in the field at the /health/diseases/alzheimers/ section.
